, evaluating CIPN with a valid, reliable, and responsive outcome measure is critical in identifying early signs of nerve damage and effects of intervention aimed at preventing long-lasting or severe neurotoxicity. There are numerous approaches to assessing
Search Results
Tiffany Li, Hannah C. Timmins, Terry Trinh, David Mizrahi, Michelle Harrison, Lisa G. Horvath, Peter Grimison, Michael Friedlander, Matthew C. Kiernan, Madeleine T. King, Claudia Rutherford, David Goldstein, and Susanna B. Park
Matthew A. Gubens and Marianne Davies
to have much poorer outcomes with single-agent immunotherapy. PD-L1 Expression ≥50% In KEYNOTE-024, pembrolizumab more than doubled median overall survival (mOS) compared with chemotherapy for patients with PD-L1 expression ≥50%, improving mOS to 30
Katherine Y. Fan, Avani S. Dholakia, Aaron T. Wild, Zheng Su, Amy Hacker-Prietz, Rachit Kumar, Mary Hodgin, Charles C. Hsu, Dung T. Le, Ana De Jesus-Acosta, Luis A. Diaz Jr, Daniel A. Laheru, Ralph H. Hruban, Elliot K. Fishman, Todd D. Brown, Timothy M. Pawlik, Christopher L. Wolfgang, Phuoc T. Tran, and Joseph M. Herman
outcomes of hospitalized patients with cancer in terms of infection, mortality, length of stay, and toxicities. The risk of cancer death (from stomach, liver, lung cancers) has been noted to be significantly higher among those with a high fasting plasma
Min Huang, Joyce O’Shaughnessy, Jing Zhao, Amin Haiderali, Javier Cortes, Scott Ramsey, Andrew Briggs, Vassiliki Karantza, Gursel Aktan, Cynthia Z. Qi, Chenyang Gu, Jipan Xie, Muhan Yuan, John Cook, Michael Untch, Peter Schmid, and Peter A. Fasching
These entities stipulate 2 criteria to establish surrogacy: (1) good correlation between the surrogate endpoint and the final outcome (individual-level association) and (2) good correlation between the treatment effect on the surrogate endpoint and the
Richard Li, Ashwin Shinde, Marwan Fakih, Stephen Sentovich, Kurt Melstrom, Rebecca Nelson, Scott Glaser, Yi-Jen Chen, Karyn Goodman, and Arya Amini
data addressing management of this rare malignancy, we used the National Cancer Database (NCDB) to assess survival outcomes according to stage and treatment strategy in patients with anal adenocarcinoma. We focused our investigation on a comparison of
Margaret M. Kozak, Clare E. Jacobson, Rie von Eyben, Erqi L. Pollom, Melinda Telli, and Kathleen C. Horst
, patients who still had residual disease in the breast did not have better outcomes compared with those who remained LN-positive. Cumulative incidence of LF, RF, and DF at 10 years by response to NAC is depicted in Table 2 , with corresponding cumulative
Emily J. Martin, Eric J. Roeland, Madison B. Sharp, Carolyn Revta, James D. Murphy, Katherine E. Fero, and Heidi N. Yeung
-center, retrospective study, we evaluated PCA use and associated clinical outcomes in patients admitted to the hospital with cancer-related pain, defined as acute or chronic physical pain attributed to cancer or its treatment. Methods Study Cohort All
Tami Borneman, Barbara F. Piper, Virginia Chih-Yi Sun, Marianna Koczywas, Gwen Uman, and Betty Ferrell
health care outcomes? JAMA 1999 ; 282 : 867 – 874 . 23. Allard P Maunsell E Labbe J Dorval M . Educational interventions to improve cancer pain control: a systematic review . J Palliat Med 2001 ; 4 : 191 – 203 . 24. Ferris FD
Claudia S.E.W. Schuurhuizen, Annemarie M.J. Braamse, Aartjan T.F. Beekman, Pim Cuijpers, Mecheline H.M. van der Linden, Adriaan W. Hoogendoorn, Hans Berkhof, Dirkje W. Sommeijer, Vera Lustig, Suzan Vrijaldenhoven, Haiko J. Bloemendal, Cees J. van Groeningen, Annette A. van Zweeden, Maurice J.D.L. van der Vorst, Ron Rietbroek, Cathrien S. Tromp-van Driel, Machteld N.W. Wymenga, Peter W. van der Linden, Aart Beeker, Marco B. Polee, Erdogan Batman, Maartje Los, Aart van Bochove, Jan A.C. Brakenhoff, Inge R.H.M. Konings, Henk M.W. Verheul, and Joost Dekker
interventions and social support for patients with diagnosed distress have been shown to be effective, 7 – 11 but so far no conclusive evidence shows that the combination of screening and subsequent treatment of distress actually improves patient outcomes
Alexandra K. Zaleta, Shauna McManus, Joanne S. Buzaglo, Eva Y. N. Yuen, Julie S. Olson, Melissa F. Miller, Karen Hurley, Lillie D. Shockney, Sara Goldberger, Mitch Golant, and Kevin Stein
Background: Despite growing recognition that patient preferences and values should inform cancer care, patients’ views continue to be under-represented. We developed a quantitative tool, Valued Outcomes in the Cancer Experience (VOICE), to measure
